Keros Therapeutics is progressing its pipeline of protein therapeutics targeting the transforming growth factor-beta (TGF-β) pathways, with its lead candidates rinvatercept and elritercept advancing through clinical trials. The company’s strategic licensing agreements with Takeda and Hansoh underpin potential commercialization while operational focus remains on pivotal Phase 2 and 3 trials. Although Keros continues to operate at a net loss typical for clinical biotechs, it maintains a robust cash position providing runway to support planned development activities. Key risks include clinical, regulatory, and commercialization uncertainties inherent in biotech development and reliance on partners for market access.